Diagnosis, Staging and Treatment of Patients with Oesophageal or Oesophagogastric Junction Cancer

Objectives

Provide a national, evidence-based clinical guideline for adults aged 18 years or over with newly diagnosed or suspected oesophageal or oesophagogastric junction cancer, covering diagnosis, staging and treatment in hospital settings.[1][2]It aims to improve the quality, safety, consistency and cost-effectiveness of care, reduce unwarranted clinical variation, and improve patient outcomes, morbidity, mortality, quality of life and care experience.[3][4][5]The guideline supports the National Cancer Strategy 2017-2026 priorities of prevention, early diagnosis, treatment and quality of life, within Ireland’s national clinical effectiveness framework.[6][7][8]

• Standardise diagnostic and staging pathways through oesophagogastroduodenoscopy and biopsy, contrast-enhanced computed tomography, endoscopic ultrasound and positron emission tomography-computed tomography according to disease stage and findings.[9][10][11][12][13]
• Improve pathological assessment through American Joint Committee on Cancer eighth-edition staging, Royal College of Pathologists reporting standards, examination of identified lymph nodes, and precise recording of circumferential resection margins.[14][15][16][17]
• Match endoscopic and surgical treatment to tumour stage, location, resectability, nodal involvement, operative fitness, comorbidities and patient preferences.[18][19][20][21][22]
• Centralise oesophageal and oesophagogastric junction surgery in designated, high-volume centres, with specialist multidisciplinary team discussion and regular outcome audit.[23][24][25]
• Integrate early, needs-based palliative care and supportive services to improve symptoms, quality of life and outcomes for patients and caregivers.[26][27][28]
• Prioritise recommendations with the strongest evidence and greatest potential impact on patients and resources, while discouraging ineffective interventions.[29][5][30]

Implementation

Deliver care through multidisciplinary teams in acute hospital services and designated cancer centres, supported by the National Cancer Control Programme, Hospital Groups, the National Clinical Effectiveness Committee and the Department of Health.[7][23][29][31]Corporate responsibility for implementation rests with hospital Chief Executive Officers, General Managers and Clinical Directors, while multidisciplinary team members implement recommendations within their professional disciplines.[1][26][2]The National Cancer Control Programme commissioned and funded the guideline, while its content was intended to remain independent of funders.[32]

• Use multidisciplinary meetings to discuss every patient with invasive or non-invasive oesophageal or oesophagogastric junction cancer, co-ordinate diagnosis and treatment decisions, and report relevant outcomes.[7][26][24][27]
• Provide surgery in designated oesophageal cancer centres through surgeons attending specialist multidisciplinary meetings; centres should undertake at least 50 resections annually and individual surgeons at least 20.[24]
• Include surgical oncology, gastroenterology, medical and radiation oncology, radiology and pathology in treatment planning, with clinical nurse specialists, dietetics, pharmacy, psycho-oncology, physiotherapy, medical social work and speech and language therapy supporting ongoing management according to need.[26][24][27]
• Implement structured plans that identify responsible leads, barriers and enablers, actions, timeframes, expected outcomes and verification arrangements.[33][8][34]
• Address service barriers through centralisation, workforce planning, staffing, training, infrastructure, equipment and service reorganisation, including access to positron emission tomography-computed tomography, endoscopic ultrasound and staging laparoscopy.[2][12][13][35][36][37]
• Disseminate guidance through professional networks, colleges, National Clinical Effectiveness Committee and National Cancer Control Programme websites, Health Service Executive communications, media, patient organisations, training and education.[8]
• Develop and update recommendations using structured clinical questions, systematic literature searches, evidence appraisal, economic assessment, stakeholder consultation and patient engagement.[32][30][38][39][40]
• Monitor implementation through quarterly National Cancer Control Programme Cancer Network Manager meetings with cancer centres, regular reviews of performance data, improvement plans and resources, and audit of guideline implementation and patient outcomes.[33][8]
• Use relevant National Cancer Strategy indicators, including centralisation of cancer surgery, multidisciplinary team discussion and increased specialist palliative care provision; audit imaging pathways, pathology reporting, surgical outcomes and palliative-care referrals where specified.[31][11][15][17][41][25][42]
• Review the guideline through literature surveillance and consider formal review three years after its August 2019 publication, with updates subject to National Clinical Effectiveness Committee approval.[43]
• Fund implementation through normal Health Service Executive service-planning processes where additional resources are required.[34][31]The budget impact analysis estimates healthcare investment of Euro 909,036 excluding service centralisation, comprising Euro 513,836 for radiology and Euro 395,200 for surgery and gastroenterology, while pathology and palliative-care recommendations have zero recorded costs.[2][44]

Monitoring & Evaluation

Implementation oversight combines hospital-level corporate responsibility, multidisciplinary team delivery, National Cancer Control Programme (NCCP) co-ordination and National Clinical Effectiveness Committee (NCEC) quality assurance. Hospital Chief Executive Officers, General Managers and Clinical Directors hold corporate responsibility, while multidisciplinary team members implement discipline-specific recommendations.[2]The NCCP Cancer Network Manager meets each cancer centre quarterly for performance monitoring and service planning.[33]

• Monitor implementation through quarterly cancer-centre meetings, regular reviews of performance data, improvement plans and resource issues, and verification arrangements in the implementation plan.[33][8]
• Audit guideline implementation and patient outcomes using the audit criteria in Appendix 7, with clinical audit progressing through planning, standards selection, performance measurement, improvement and sustaining improvement.[8][44]
• Measure implementation against National Cancer Strategy indicators, including centralisation of cancer surgery, multidisciplinary discussion of cancer cases and increased specialist palliative-care provision.[31][11]
• Audit adherence to the NCCP diagnostic-staging algorithm, appropriate use of positron emission tomography-computed tomography where metastases are already visible on computed tomography, pathology-template recording of circumferential resection margins, surgical outcomes and palliative-care referrals.[12][15][17][25][42]
• Assess surgeon and team outcomes against risk-adjusted international benchmark standards, supported by accurate data capture and regular outcome review.[24][27]
• Conduct literature surveillance and consider the guideline for review three years after its August 2019 publication; submit interim or three-year updates to NCEC approval.[43]

Relevant service standards include discussion of every diagnosed cancer case at a multidisciplinary team meeting, regular audit in designated oesophageal cancer centres, and a target for 95% of cancer surgery to occur in approved centres by 2020.[7][26][23]The guideline also supports repeat endoscopic surveillance after endotherapy and continuous assessment of palliative-care needs throughout illness.[20][28]Detailed national reporting templates, surveillance schedules and a comprehensive indicator set are not specified beyond these audits, performance reviews and Cancer Strategy indicators.[8][11]

Costing & Financing

The guideline identifies a healthcare investment requirement of Euro 909,036 for implementation, excluding service centralisation, which is to be addressed through normal Health Service Executive service-planning processes.[2]The budget impact analysis allocates Euro 513,836 to radiology and Euro 395,200 to surgery and gastroenterology, while pathology and palliative-care recommendations carry zero recorded implementation cost.[26][2]

• Fund expanded access to positron emission tomography-computed tomography and endoscopic ultrasound, estimated at Euro 130,691 annually for early-stage imaging and Euro 383,145 annually for advanced-stage imaging.[12][13]
• Provide protected day-ward capacity, staff and surgical time for staging laparoscopy, estimated at Euro 395,200 for 100 patients annually.[35]
• Use existing National Service Plan allocations for recommendations already funded, including several current-practice, endoscopic, enhanced-recovery, surgical-centralisation and palliative-care initiatives.[11][36][41][42]
• Seek additional resources through Health Service Executive service planning where implementation creates new resource requirements.[34]
• Consider potential but unquantified savings from avoiding unnecessary positron emission tomography-computed tomography in early-stage disease and from novel surgical techniques that reduce hospital stay.[2]

Economic evidence informs recommendations but has limited direct transferability to Ireland where it relies on British, United States, Australian or Dutch data.[45][46][47]Endoscopic ultrasound was associated with a Euro 3,423 resource saving per patient in a National Health Service assessment, while positron emission tomography-computed tomography restaging after neoadjuvant treatment was estimated to save Euro 2,220 per patient.[48][49]Ireland has no explicit non-drug cost-effectiveness threshold, although approximately Euro 45,000 per quality-adjusted life-year is conventionally considered cost-effective.[45]The document does not specify a dedicated financing source, funding gap or total budget for centralisation.[2][34]